Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has released the results of a study evaluating Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection), which showed that Lantus and Apidra before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin.
Subscribe to our email newsletter
Sanofi-aventis said that separate injections are being used by people following a basal-bolus insulin of a basal insulin and a mealtime insulin. The regimen is designed to address hyperglycemia before it happens by providing adequate insulin to cover fasting and prandial insulin needs.
Sanofi-aventis stated that a premix insulin regimen combines prandial insulin analogs and the intermediate-acting insulin, NPH, in one injection. The results of this study demonstrated that patients using a basal-bolus regimen, with Lantus and Apidra, reported improved outcomes and quality of life.
Donald Simonson, ScD of the endocrinology, diabetes and hypertension division of Brigham and Women’s Hospital in Boston, Massachusetts and principal investigator of the study, said: “These results indicate that patients treated with a basal-bolus insulin regimen consisting of Lantus and Apidra showed an improved quality of life and patient reported outcomes compared to those treated with premix analog insulin.”